| • | Application No. | Applicant(s) | |
|---|---|----------------------------------|--|
| Notice of Allowability | 10/674,744 | SACKEYFIO ET AL. | |
| | Examiner | Art Unit | |
| | Konata M. George | 1616 | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to amendment filed January 4, 2005. | | | |
| <u> </u> | | | |
| 2. Mathematical The allowed claim(s) is/are 1-8. | | | |
| 3. The drawings filed on are accepted by the Examine | r. | | |
| 4. | | | |
| Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material | 5. ☐ Notice of Informal P 6. ☐ Interview Summary Paper No./Mail Dat 7. ☐ Examiner's Amendr 8. ☑ Examiner's Stateme 9. ☐ Other | (PTO-413), te ment/Comment | |

DETAILED ACTION

Claims 1-8 are pending in this application.

Action Summary

- 1. The rejection of claims 1-6 and 8 under 35 U.S.C. 103(a) over Smith is hereby withdrawn as applicant has amended the claim 1 to recite certain modes of dosage, with is not taught by the prior art.
- 2. The rejection of claims 1, 7 and 8 under the judicially created doctrine of obviousness-type double patenting over claims 1, 3, 5 and 7 of U.S. application no. 10/716,823 is hereby withdrawn.

Statement of Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach,
disclose nor make obvious a pharmaceutical composition comprising amoxapine and a
corticosteroid in amounts that when administered together inhibit or reduce
inflammation. Wherein, the composition is formulated for oral, rectal, intravenous, etc.
administration. The closet prior art of Smith does not teach administering the
composition in any other manner than as a topical preparation.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Application/Control Number: 10/674,744

Art Unit: 1616

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

Conclusion

4. Claims 1-8 are allowed.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Konata M. George, whose telephone number is

(571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday

to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for

the organization where this application or proceeding is assigned are (703) 872-9306 for

regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is

(571) 272-1600.

Konata M. George

SAELLEY A. DODSON PRIMARY EXAMINER Page 3